Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3

Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3

Submitted by admin on November 27, 2018 - 11:35pm
Source: 
Fierce Biotech
News Tags: 
Halozyme
clinical trials
PEGPH20
metastatic prostate cancer
Headline: 
Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3
snippet: 

Halozyme has dropped the progression-free survival (PFS) co-primary endpoint from its phase 3 trial of PEGPH20 in metastatic pancreatic cancer. 

Do Not Allow Advertisers to Use My Personal information